23andMe (ME) Competitors $4.65 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ME vs. VLTA, EMBK, SKIN, HLLY, OPFI, XERS, RGNX, DNA, TERN, and NLTXShould you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Volta (VLTA), Embark Technology (EMBK), Beauty Health (SKIN), Holley (HLLY), OppFi (OPFI), Xeris Biopharma (XERS), REGENXBIO (RGNX), Ginkgo Bioworks (DNA), Terns Pharmaceuticals (TERN), and Neoleukin Therapeutics (NLTX). 23andMe vs. Volta Embark Technology Beauty Health Holley OppFi Xeris Biopharma REGENXBIO Ginkgo Bioworks Terns Pharmaceuticals Neoleukin Therapeutics Volta (NYSE:VLTA) and 23andMe (NASDAQ:ME) are both small-cap auto/tires/trucks companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking. Which has stronger earnings & valuation, VLTA or ME? Volta has higher earnings, but lower revenue than 23andMe. Volta is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolta$50.23M2.89-$276.60M-$1.52-0.5723andMe$219.64M0.52-$666.70M-$26.20-0.18 Does the MarketBeat Community favor VLTA or ME? 23andMe received 3 more outperform votes than Volta when rated by MarketBeat users. Likewise, 60.00% of users gave 23andMe an outperform vote while only 26.47% of users gave Volta an outperform vote. CompanyUnderperformOutperformVoltaOutperform Votes926.47% Underperform Votes2573.53% 23andMeOutperform Votes1260.00% Underperform Votes840.00% Do insiders & institutionals believe in VLTA or ME? 20.4% of Volta shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 26.1% of Volta shares are held by company insiders. Comparatively, 26.3% of 23andMe shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is VLTA or ME more profitable? 23andMe has a net margin of -317.03% compared to Volta's net margin of -496.15%. 23andMe's return on equity of -83.22% beat Volta's return on equity.Company Net Margins Return on Equity Return on Assets Volta-496.15% -110.38% -58.43% 23andMe -317.03%-83.22%-51.12% Does the media refer more to VLTA or ME? In the previous week, 23andMe had 9 more articles in the media than Volta. MarketBeat recorded 9 mentions for 23andMe and 0 mentions for Volta. Volta's average media sentiment score of 0.02 beat 23andMe's score of -0.08 indicating that Volta is being referred to more favorably in the media. Company Overall Sentiment Volta Neutral 23andMe Neutral Do analysts recommend VLTA or ME? 23andMe has a consensus target price of $9.40, indicating a potential upside of 102.15%. Given 23andMe's higher possible upside, analysts plainly believe 23andMe is more favorable than Volta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Volta 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A23andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Which has more risk and volatility, VLTA or ME? Volta has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Summary23andMe beats Volta on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get 23andMe News Delivered to You Automatically Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ME vs. The Competition Export to ExcelMetric23andMePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$113.97M$7.02B$5.32B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-0.1810.75121.3415.54Price / Sales0.52396.531,497.9292.41Price / Cash1.6247.4339.6734.18Price / Book0.605.604.755.07Net Income-$666.70M$153.56M$118.54M$225.38M7 Day Performance-0.43%-1.46%-0.39%0.07%1 Month Performance-36.99%15.32%6.05%3.93%1 Year Performance-71.65%43.07%38.13%32.51% 23andMe Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ME23andMe1.9247 of 5 stars$4.65flat$9.40+102.2%-71.6%$113.99M$219.64M-0.18770VLTAVoltaN/A$0.86flatN/AN/A$145.10M$50.23M-0.57253EMBKEmbark TechnologyN/A$2.88flatN/AN/A$69.26MN/A-0.37329SKINBeauty Health2.9405 of 5 stars$1.77+7.3%$2.46+38.9%-58.1%$219.52M$398M-2.131,030HLLYHolley4.2836 of 5 stars$2.81+2.6%$6.54+132.6%-37.2%$336.58M$659.70M14.791,633Upcoming EarningsNews CoverageOPFIOppFi1.4482 of 5 stars$5.38+6.5%$5.00-7.1%+123.5%$464.03M$508.95M67.26570Upcoming EarningsXERSXeris Biopharma3.8147 of 5 stars$3.23+0.9%$4.67+44.5%+72.7%$474.42M$181.41M-7.51290News CoveragePositive NewsRGNXREGENXBIO4.5128 of 5 stars$9.38+0.3%$35.45+278.0%-38.1%$462.02M$89.04M-1.78344Upcoming EarningsDNAGinkgo Bioworks0.9417 of 5 stars$8.28+1.5%$4.16-49.8%N/A$460.20M$251.46M-0.451,218Positive NewsTERNTerns Pharmaceuticals4.6125 of 5 stars$6.51-2.4%$15.90+144.2%+32.2%$457.91M$1M-4.9340Analyst ForecastNews CoverageNLTXNeoleukin TherapeuticsN/A$48.37+0.4%N/A+240.8%$454.58MN/A-15.5590 Related Companies and Tools Related Companies VLTA Competitors EMBK Competitors SKIN Competitors HLLY Competitors OPFI Competitors XERS Competitors RGNX Competitors DNA Competitors TERN Competitors NLTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ME) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
